PMID- 9307226
OWN - NLM
STAT- MEDLINE
DCOM- 19971015
LR  - 20190826
IS  - 0165-5728 (Print)
IS  - 0165-5728 (Linking)
VI  - 78
IP  - 1-2
DP  - 1997 Sep
TI  - A genetically modified allogeneic cellular vaccine generates MHC class 
      I-restricted cytotoxic responses against tumor-associated antigens and protects 
      against CNS tumors in vivo.
PG  - 34-46
AB  - An active immunotherapeutic strategy using transfected allogeneic cells for 
      targeting the mutant epidermal growth factor receptor (EGFRvIII) on intracranial 
      tumors was examined. Immunization with allogeneic 300.19/EGFRvIII cells induced 
      CD8+ cytotoxic T-lymphocytes against EGFRvIII bearing syngeneic B16-F10 melanoma 
      or 560 astrocytoma cells (H-2b), but not against allogeneic NR6 cells (H-2q) also 
      bearing EGFRvIII significant NK cell activity was also noted in vitro. 
      Vaccination protected against intracranial challenge with EGFRvIII-positive 
      tumor, with 50% long term survival. In vivo depletions of effector cell subsets 
      demonstrated the requirements for both CD8+ and CD4+ T-cells but not NK cells in 
      producing this protective effect. These data demonstrate the generation of 
      significant, antigen-specific and MHC class I-restricted cytotoxic immune 
      responses which are effective against tumors present in the CNS.
FAU - Ashley, D M
AU  - Ashley DM
AD  - Preuss Laboratory for Brain Tumor Research, Duke University Medical Center, 
      Durham, NC 27710, USA.
FAU - Sampson, J H
AU  - Sampson JH
FAU - Archer, G E
AU  - Archer GE
FAU - Batra, S K
AU  - Batra SK
FAU - Bigner, D D
AU  - Bigner DD
FAU - Hale, L P
AU  - Hale LP
LA  - eng
GR  - CA11898/CA/NCI NIH HHS/United States
GR  - CA61227/CA/NCI NIH HHS/United States
GR  - NS 20023/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Netherlands
TA  - J Neuroimmunol
JT  - Journal of neuroimmunology
JID - 8109498
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/genetics/*immunology
MH  - Cancer Vaccines/*immunology
MH  - Central Nervous System Neoplasms/immunology/metabolism/*prevention & control
MH  - *Cytotoxicity, Immunologic
MH  - ErbB Receptors/genetics/immunology
MH  - Female
MH  - Genetic Techniques
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Immunization
MH  - Mice
MH  - Mutation
MH  - Neoplasm Transplantation
MH  - Survival Analysis
MH  - Transfection
MH  - Tumor Cells, Cultured
EDAT- 1997/10/23 22:13
MHDA- 2000/06/01 09:00
CRDT- 1997/10/23 22:13
PHST- 1997/10/23 22:13 [pubmed]
PHST- 2000/06/01 09:00 [medline]
PHST- 1997/10/23 22:13 [entrez]
AID - S0165-5728(97)00080-5 [pii]
AID - 10.1016/s0165-5728(97)00080-5 [doi]
PST - ppublish
SO  - J Neuroimmunol. 1997 Sep;78(1-2):34-46. doi: 10.1016/s0165-5728(97)00080-5.